

SAR by Oxime-Containing Peptide Libraries: Application to Tsg101 Ligand Optimization

Fa Liu,^[a] Andrew G. Stephen,^[b] Abdul A. Waheed,^[c] M. Javad Aman,^[d] Eric O. Freed,^[c] Robert J. Fisher,^[b] and Terrence R. Burke, Jr.*^[a]

HIV-1 viral assembly requires a direct interaction between a Pro-Thr-Ala-Pro ("PTAP") motif in the viral protein Gag-p6 and the cellular endosomal sorting factor Tsg101. In an effort to develop competitive inhibitors of this interaction, an SAR study was conducted based on the application of post solid-phase oxime for-

mation involving the sequential insertion of aminoxy-containing residues within a nonamer parent peptide followed by reaction with libraries of aldehydes. Approximately 15–20-fold enhancement in binding affinity was achieved by this approach.


Introduction

Chemical modulation of protein–protein interactions can offer potential new approaches to therapeutic development.^[1–5] However, designing binding antagonists starting from peptides and peptide mimetics modeled on consensus recognition sequences may suffer from a lack of detailed solution NMR or X-ray crystallographic data.^[6–11] Where the binding interactions of amino acid residues with the target protein are not known, a stepwise structural exploration along the ligand backbone can be undertaken. One way to achieve this is by inserting at discrete points, amino acids such as L-2,3-diaminopropionic acid that contain latent reactive handles amenable to library elaboration following the conclusion of peptide synthesis.^[12] This tactic of delayed diversification allows a more facile generation of libraries than would be possible by constructing the peptides using collections of individually preformed amino acids. To facilitate this type of peptide modification, we have recently prepared orthogonally protected hydrazide and aminoxy-containing α -amino acids that can be incorporated into peptides using standard solid-phase Fmoc chemistries. Subsequent post solid-phase library diversification can be achieved by reaction with collections of aldehydes.^[13–15]

In the current paper, we extend this approach by sequentially examining each residue of a target peptide via a library of oxime derivatives. This is achieved through the initial solid-phase synthesis of a series of peptides in which each amino acid of the parent sequence is replaced by one or more aminoxy-containing residues. Following cleavage of the peptides

from the resin and HPLC purification, each aminoxy-containing peptide (**1**, Scheme 1) is reacted individually with a range of aldehydes to yield libraries consisting of functionalized oximes appended from the peptide backbone by tethers of various length. We have found that the resulting peptide libraries (**2**) are sufficiently pure (>90%) for direct biological evaluation.

Viral budding represents a promising but unexploited process for antiretroviral inhibitors.^[16–18] In order to examine a residue-by-residue oxime library scan on a potentially important peptide target, we focused our attention on a critical sequence involved with the budding of HIV-1. In the case of HIV-1, budding requires a direct interaction between a Pro-Thr-Ala-Pro ("PTAP") motif in the viral protein Gag-p6 and the cellular endosomal sorting factor Tsg101.^[19] Inhibition of this Gag-Tsg101 interaction may provide the basis for a new class of AIDS therapies.^[17,20] Tsg101 binding data for a series of peptides containing the "PTAP" sequence showed that the nonamer sequence "P¹E²P³T⁴A⁵P⁶P⁷E⁸E⁹" retains modest binding affinity ($K_d \sim 50\text{--}60 \mu\text{M}$).^[21] NMR solution studies of a "PEPTAPPEE" peptide binding to Tsg101 have indicated accommodation of the



Scheme 1. Oxime-based library approach.

[a] Dr. F. Liu, Dr. T. R. Burke, Jr.
Laboratory of Medicinal Chemistry, CCR, NCI-Frederick
Building 376 Boyles Street, Frederick, MD 21702 (USA)
Fax: (+1) 301-846-6033
E-mail: tburke@helix.nih.gov

[b] Dr. A. G. Stephen, Dr. R. J. Fisher
Protein Chemistry Laboratory, Advanced Technology Program
SAIC-Frederick, Inc. NCI-Frederick
Frederick, MD 21702 (USA)

[c] Dr. A. A. Waheed, Dr. E. O. Freed
HIV Drug Resistance Program, CCR, NCI-Frederick
Frederick, MD 21702 (USA)


[d] Dr. M. J. Aman
U.S. Army Medical Research Institute for Infectious Diseases
Frederick, MD 21702 (USA)

Supporting information for this article is available on the WWW under <http://www.chembiochem.org> or from the author.

A⁵P⁶ side chains within a distinct pocket.^[22,23] This suggested recognition features shared by SH3 and WW domains for proline residues.^[24] However, replacement of the key proline residue with *N*-alkylglycines ("peptoids") or related constructs^[13] did not increase binding affinity to the extent expected based on literature precedence.^[25] Replacing the A⁵ residue with a variety of amino acids also failed to significantly improve binding affinity.^[26] The ambiguous nature of the binding interactions of the parent nonamer supported the undertaking of a systematic examination of each residue using an oxime library approach.

Results and Discussion

The protected aminoxy-containing amino acid analogues **3–7**^[14,15] (Scheme 2) were used to prepare twelve parent peptides (**8–19**, Table 1) by standard solid-phase Fmoc chemistries. Re-



Scheme 2. Protected aminoxy-containing amino acid reagents.

Table 1. Aminoxy-containing parent peptides.^[a]

No	Peptide sequence	Aminoxy-Residue ^[b]
8	FITC-Ava- PEPTAP PEE	<i>trans</i> -4-aminoxy-Pro (6)
9	FITC-Ava- <u>PEPTAP</u> PEE	<i>cis</i> -4-aminoxy-Pro (5)
10	FITC-Ava-PE PTAP PEE	4-aminoxy-Abu (4)
11	FITC-Ava-PE PTAP PEE	<i>trans</i> -4-aminoxy-Pro (6)
12	FITC-Ava-PE <u>PTAP</u> PEE	<i>cis</i> -4-aminoxy-Pro (5)
13	FITC-Ava-PE PTA PEE	3-aminoxy-Ala (3)
14	FITC-Ava-PE PTA PEE	<i>trans</i> -4-aminoxy-Pro (6)
15	FITC-Ava-PE <u>PTA</u> PEE	<i>cis</i> -4-aminoxy-Pro (5)
16	FITC-Ava-PE PTA PEE	<i>trans</i> -4-aminoxy-Pro (6)
17	FITC-Ava-PE <u>PTA</u> PEE	<i>cis</i> -4-aminoxy-Pro (5)
18	FITC-Ava-PE PTA PEE	4-aminoxy-Abu (4)
19	FITC-Ava-PE <u>PTA</u> PEE	4-aminoxy-Abu (4)

[a] Bold underlined indicates residue replaced by aminoxy-containing surrogate. [b] Protected reagent used to insert the aminoxy-containing residue.

placement of T⁴ was by 3-aminoxy-Ala (**3**); glutamic acid residues were replaced using 4-aminoxy-aminobutyric acid (**4**), and proline residues were replaced using the 4-aminoxy-Pro derivatives **5–7** as indicated in Table 1. The A⁵ residue was left unaltered.^[26] In order to facilitate binding analysis using fluorescence anisotropy, the N terminus of each peptide was labeled with fluoresceine isothiocyanate linked by a 5-aminovaleic acid spacer (FITC-Ava).^[13] For the HPLC purified parent aminoxy-containing peptides (**8–19**), a library of oxime derivatives was generated by reacting with a series of commercially obtained aldehydes (**a–l**, Table 2). The resulting oxime-contain-

ing peptides were sufficiently pure (>90%) for direct Tsg101 binding studies as summarized in Table 2.

All parent peptides having free unreacted aminoxy groups, (except **14** and **15**, which involved replacement of the critical P⁶ residue) retained binding affinities similar to the wild-type nonamer. This indicated that introduction of the aminoxy groups did not significantly disrupt native binding interactions and that the aminoxy-containing peptides provided suitable platforms for further SAR studies. Peptides **11** and **12**, having *trans* and *cis* substituted 4-aminoxy-proline residues at the P³ position, showed markedly different *K_d* values (68 μM and 214 μM, respectively). Oxime scans of these two peptides (**11a–l** and **12a–l**) provided a wide range of binding affinities. Peptide **11j** (*K_d*=3.3 μM) exhibited a binding enhancement of 15–20 fold relative to the wild-type peptide (*K_d*~50–60 μM). In contrast, the P⁶ position was intolerant to modification. Both the parent aminoxy peptides **14** and **15** as well as all oxime derivatives **14a–l** and **15a–l**, exhibited significantly diminished binding affinities. These results are consistent with our finding that modification of the P⁶ pyrrolidine ring by insertion of F, N, or O substituents adversely affects binding.^[27]

Although replacement of T⁴ with an unsubstituted aminoxy-containing residue (peptide **13**, *K_d*=64 μM) retained the binding affinity of the parent wild-type nonamer, further modification by oxime derivatization (peptides **13a–l**) decreased the binding affinity. This potentially indicates that a free amino or hydroxyl group is needed at this site, possibly to serve as a hydrogen-bond donor. The positions P¹ (**8a–l** and **9a–l**), E² (**10a–l**), P⁷ (**16a–l**), and E⁸ (**18a–l**) were relatively insensitive to structural modifications. However, in some cases up to fivefold binding enhancement could be achieved (for example, **9f**, **10i**, **16f**, **16i**, **16j**, **18c**, **18g**, and **18i**). Interestingly, both of the parent peptides **16** and **17** having unsubstituted *trans* and *cis* 4-aminoxyproline-residues at the P⁷ position, exhibited similar binding affinities (43 μM and 55 μM, respectively), yet only oxime derivatives of **16** resulted in higher affinity. Modification of **17** did not benefit binding. Changes at the E⁹ position (**19a–l**) also had little effect on binding. These data are summarized graphically in Figure 1 as fold change in Tsg101 binding affinity.

As the 3,4-dimethoxybenzyl oxime-containing peptide **11j** showed a 15–20-fold binding enhancement relative to the wild-type nonamer sequence, a more focused library was prepared by reacting **11** with ten benzaldehydes containing one or more hydroxyl or methoxyl groups.^[28] It was found that although 3-methoxy substituents contributed more to binding enhancement than 4-methoxy substituents, the original 3,4-dimethoxy-containing **11j** exhibited the highest affinity of the series.

Using **11j** as a starting point, the P⁷ and E⁸ sites were chosen for secondary modification. This was based on the fact that these locations were among the farthest removed from P³, the site of oxime derivatization in **11j**. In order to withstand the 90% TFA conditions necessary to cleave peptides from the solid-phase resin, the P³ oxime bond in **11j** was replaced by an amide bond to yield peptide **20** (Scheme 3). This was accomplished using methyltrityl-protected reagent **7**, which was de-

Table 2. Tsg101 binding to oxime-containing peptide libraries.^[a, b]

Modified residue parent peptide	P ¹		E ²		P ³		T ⁴		(A ⁵)P ⁶		P ^{7(c)}		E ⁸	E ⁹
	8	9	10	11	12	13	14	15	16	17	18	19		
– Aldehyde ^[d] (no aldehyde)	37	56	22	68	214	64	n.b. ^[e]	n.b.	43	55	47	79		
a <chem>CCCCC=O</chem>	45	23	24	24	88	246	n.b.	n.b.	41	42	28	132		
b <chem>HOOC-CH2-CHO</chem>	53	62	15	92	188	n.f. ^[f]	n.b.	n.b.	27	75	28	56		
c <chem>c1ccc(cc1)CC=O</chem>	50	42	19	34	24	n.f.	n.b.	n.b.	26	83	18	77		
d <chem>c1ccoc1C=O</chem>	45	44	20	42	16	400	n.b.	n.b.	30	48	25	78		
e <chem>c1ccccc1C=O</chem>	38	19	29	33	16	n.f.	n.b.	n.b.	26	64	23	88		
f <chem>C=C(C)C=O</chem>	54	14	39	51	15	n.f.	n.b.	n.b.	13	58	26	107		
g <chem>CN(C)c1ccc(C=O)cc1</chem>	35	105	17	19	58	n.f.	n.b.	n.b.	17	42	13	124		
h <chem>[O-][N+](=O)c1ccc(C=O)cc1</chem>	41	74	16	17	156	n.f.	n.b.	n.b.	21	91	28	82		
i <chem>OC(=O)c1ccc(C=O)cc1</chem>	18	23	11	27	71	n.f.	n.b.	n.b.	16	93	18	89		
j <chem>COc1ccc(C=O)cc1</chem>	42	38	21	3.3	121	n.f.	n.b.	n.b.	16	114	20	54		
k <chem>Fc1c(F)c(C=O)cc1F</chem>	42	20	27	46	177	n.f.	n.b.	n.b.	32	139	21	33		
l <chem>c1ccc(cc1)Oc2ccc(C=O)cc2</chem>	54	23	26	9.5	87	n.f.	n.b.	n.b.	30	54.5	35	55		

[a] Numerical data represent K_d values [μM] obtained as indicated in ref. [13]. [b] Wild-type peptide FITC-Ava-PEPTAPPEE-amide $K_d \sim 50\text{--}60 \mu\text{M}$. [c] Data previously reported in ref. [14]. [d] Aldehyde used to form the indicated oxime-containing peptide. [e] n.b. = no binding. [f] n.f. = no fit, suggesting weak binding ($K_d > 500 \mu\text{M}$).





Figure 1. Graphical depiction of maximum effects on Tsg101 binding affinity achieved by modification of each residue of the wild-type sequence.

protected on the resin and acylated with 3,4-dimethoxybenzoic acid active ester. A similar hydrolytically stable version of **16j** (peptide **21**) was prepared.

Both **20** and **21** exhibited an approximately threefold loss of binding affinity relative to their parent oximes (**20**, $K_d = 9 \mu\text{M}$; **21**, $K_d = 41 \mu\text{M}$). Bis-aminoxy-containing peptides **22** and **23** were prepared ($K_d = 8.9 \mu\text{M}$ and $12 \mu\text{M}$, respectively) and oxime libraries were generated from a selection of aldehydes determined by previous oxime binding data. Most of these “bi-modified” peptides exhibited a slight increase in binding affinity, with peptide **24** showing the greatest increase ($K_d = 3.1 \mu\text{M}$; fourfold relative to **23**).^[29]

Conclusions

In summary, an SAR study was conducted based on the application of post solid-phase oxime formation and utilizing aminoxy-containing residues substituted in a nonamer parent peptide. Approximately 15–20-fold enhancement in binding affinity was achieved by this approach. The methodology may be broadly applicable for peptide ligand optimization, especial-



Scheme 3. Structures of Tsg101-binding peptides.

ly in the early stages of SAR development where a three-dimensional knowledge of protein–ligand interactions is lacking.

Experimental Section

Peptide synthesis: Peptides were synthesized using commercially available Fmoc protected proline derivatives. Peptides were synthesized on NovaSyn®TGR resin (purchased from Novabiochem,

cat. no. 01–64–0060) using standard Fmoc solid-phase protocols. 1-Hydroxybenzotriazole (HOBT) and *N,N'*-diisopropylcarbodiimide (DIC) were used as coupling reagents for primary amines (single coupling, 2 h); Except as noted below, bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP) was used for coupling of secondary amines (double coupling, 2 h). Coupling of Fmoc-*trans*-4-hydroxyproline-OH, Fmoc-*cis*-4-hydroxyproline-OH and Fmoc-*trans*-3-hydroxyproline-OH was conducted by using 2-(1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate

(HBTU) and HOBt (single coupling, 2 h); followed by masking the hydroxyl group with trityl chloride (TrtCl) (10 equiv) and DIPEA (12 equiv) in DCM/DMF (1:1) at RT (repeated once, 1 h each). The final coupling step was conducted using fluoresceine isothiocyanate (5.0 equiv) and *N,N*-diisopropylethylamine (DIPEA) (5.0 equiv) in NMP (overnight). The resin was washed (DMF, MeOH, DCM and Et₂O) then dried under vacuum (overnight). Peptides were cleaved from the resin (200 mg) by treatment with trifluoroacetic acid/trisobutylsilane/H₂O (90:5:5; 5 mL, 4 h). The resin was removed by filtration and the filtrate was concentrated under vacuum, then precipitated with Et₂O, and the precipitate was washed with Et₂O. The resulting solid was dissolved in 50% aqueous acetonitrile (5 mL) and purified by reversed-phase preparative HPLC using a Phenomenex C18 column (21 mm Ø×250 mm, cat. no: 00G-4436-P0) with a linear gradient from 0% aqueous acetonitrile (0.1% trifluoroacetic acid) to 80% acetonitrile (0.1% trifluoroacetic acid) over 35 min (flow rate of 10.0 mL min⁻¹, detection at 220 nm). Lyophilization provided products as yellow powders.

Post solid-phase diversification: A mixture of HPLC-purified aminoxy-proline containing peptide (**8–19**; 15 mM in DMSO, 10 µL), aldehyde (**a–l**; 15 mM in DMSO, 10 µL), and acetic acid (70 mM in DMSO, 10 µL) was gently agitated at room temperature (overnight). Examination by HPLC showed the reactions had gone to completion to produce oxime products in higher than 90% purity. Crude reaction mixtures were used directly for biological evaluation.

Acknowledgements

The Work was supported in part by the Intramural Research Program of the NIH, Center for Cancer Research, NCI-Frederick, and the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, neither does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Keywords: aldehydes • combinatorial chemistry • oximes • peptidomimetics • Tsg101

- [1] A. Loregian, H. S. Marsden, G. Palu, *Rev. Med. Virol.* **2002**, *12*, 239–262.
- [2] A. Loregian, G. Palu, *J. Cell. Physiol.* **2005**, *204*, 750–762.
- [3] M. Arkin, *Curr. Opin. Chem. Biol.* **2005**, *9*, 317–324.
- [4] P. Chène, *ChemMedChem* **2006**, *1*, 400–411.
- [5] J. A. Wells, C. L. McClendon, *Nature* **2007**, *450*, 1001–1009.
- [6] J. A. Kritzer, O. M. Stephens, D. A. Guarracino, S. K. Reznik, A. Schepartz, *Bioorg. Med. Chem.* **2004**, *12*, 11–16.
- [7] L. O. Sillerud, R. S. Larson, *Curr. Protein Pept. Sci.* **2005**, *6*, 151–169.
- [8] M. C. Hammond, B. Z. Harris, W. A. Lim, P. A. Bartlett, *Chem. Biol.* **2006**, *13*, 1247–1251.
- [9] J. Liu, C. Li, S. Ke, S. D. Satyanarayanajais, *J. Med. Chem.* **2007**, *50*, 4038–4047.
- [10] E. Nieddu, S. Pasa, *Curr. Top. Med. Chem.* **2007**, *7*, 21–32.
- [11] J. D. Sadowsky, W. D. Fairlie, E. B. Hadley, H.-S. Lee, N. Umezawa, Z. Nikolovska-Coleska, S. Wang, D. C. S. Huang, Y. Tomita, S. H. Gellman, *J. Am. Chem. Soc.* **2007**, *129*, 139–154.
- [12] J. H. Lee, S. K. Nandy, D. S. Lawrence, *J. Am. Chem. Soc.* **2004**, *126*, 3394–3395.
- [13] F. Liu, A. G. Stephen, C. S. Adamson, K. Gousset, M. J. Aman, E. O. Freed, R. J. Fisher, T. R. Burke Jr., *Org. Lett.* **2006**, *8*, 5165–5168.
- [14] F. Liu, A. G. Stephen, R. J. Fisher, T. R. Burke Jr., *Bioorg. Med. Chem. Lett.* **2008**, *18*, 1096–1101.
- [15] F. Liu, J. Thomas, T. R. Burke, Jr., *Synthesis*; in press.
- [16] J. A. Turpin, *Exp. Rev. Anti-Infective Ther.* **2003**, *1*, 97–128.
- [17] M. Shehu-Xhilaga, S. Ablan, D. G. Demirov, C. Chen, R. C. Montelaro, E. O. Freed, *J. Virol.* **2004**, *78*, 724–732.
- [18] P. P. Klinger, U. Schubert, *Exp. Rev. Anti-Infective Ther.* **2005**, *3*, 61–79.
- [19] J. E. Garrus, U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Côté, R. L. Rich, D. G. Myszka, W. I. Sundquist, *Cell* **2001**, *107*, 55–65.
- [20] D. G. Demirov, A. Ono, J. M. Orenstein, E. O. Freed, *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 955–960.
- [21] See Supporting Information I.
- [22] O. Pornillos, S. L. Alam, D. R. Davis, W. I. Sundquist, *Nat. Struct. Mol. Biol.* **2002**, *9*, 812–817.
- [23] O. Pornillos, S. L. Alam, R. L. Rich, D. G. Myszka, D. R. Davis, W. I. Sundquist, *EMBO J.* **2002**, *21*, 2397–2406.
- [24] E. O. Freed, *Trends Microbiol.* **2003**, *11*, 56–59.
- [25] J. T. Nguyen, C. W. Turck, F. E. Cohen, R. N. Zuckermann, W. A. Lim, *Science* **1998**, *282*, 2088–2092.
- [26] See Supporting Information II.
- [27] See Supporting Information III.
- [28] See Supporting Information IV.
- [29] See Supporting Information V.

Received: April 24, 2008

Published online on July 23, 2008